OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Cancer is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Subscription & copyright page	334
Engineering growth factor ligands and receptors for therapeutic innovation	213
Platelets: tailoring metastasis treatment	213
Revumenib: a new era in acute leukemia treatment	196
Spliced to kill: RNA mis-splicing derived cancer neoantigens	192
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	175
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	171
FBXW10: a male-biased E3 ligase in liver cancer	163
Tumor-resident microbes: the new kids on the microenvironment block	152
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	152
Advisory Board and Contents	151
Navigating life as an early career researcher	151
Subscription & copyright page	148
Subscription and copyright page	145
Accessing the vasculature in cancer: revising an old hallmark	134
Leveraging circulating microbial DNA for early cancer detection	133
Onco-condensates: formation, multi-component organization, and biological functions	130
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	124
Radiotherapy and immunotherapy: open questions and future strategies	124
Engine shutdown: migrastatic strategies and prevention of metastases	123
Subscription & copyright page	102
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	89
Diet, nutrient supply, and tumor immune responses	87
GOT2 consider the tumor microenvironment	87
Gut microbiota – a double-edged sword in cancer immunotherapy	86

cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	82
Pannexin biology and emerging linkages to cancer	82
Oncogenic competence: balancing mutations, cellular state, and microenvironment	76
Benefits and opportunities of the transgenic Oncopig cancer model	76
Regulation of metastatic organotropism	76
Crosstalk of T cells within the ovarian cancer microenvironment	74
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	73
Chromatin as an old and new anticancer target	70
Tumor immunology CRISPR screening: present, past, and future	70
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	67
Chromosomal instability and aneuploidy as causes of cancer drug resistance	67
Recent developments in myeloid immune modulation in cancer therapy	66
Cell death, therapeutics, and the immune response in cancer	63
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	60
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	59
Subscription & copyright page	58
Advisory Board and Contents	58
Advisory Board and Contents	58
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	57
Insights on ErbB glycosylation – contributions to precision oncology	56
Subscription & copyright page	55
Advisory Board and Contents	55
Scaling data toward pan-cancer foundation models	52
β-Galactosylceramidase in cancer: friend or foe?	52
Genetic immune escape in cancer: timing and implications for treatment	52
Organellar pH as an emerging vulnerability to exploit in cancer	51
Palmitate paves the way to lung metastasis	50
Clinical and translational relevance of intratumor heterogeneity	50
The emerging field of oncolytic virus-based cancer immunotherapy	49
Cancer catecholamine conundrum	49
Inflammation: the incubator of the tumor microenvironment	49
Advisory Board and Contents	48
Advisory Board and Contents	47
Advisory Board and Contents	46
Advisory Board and Contents	45
Subscription and copyright page	45
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	45
Subscription & copyright page	44
B7-H3: a robust target for immunotherapy in prostate cancer	43
Redefining precision cancer prevention to promote health equity	43
Prospects for understanding and exploiting the consequences of hyperactivation lethality	43
Circulating cell-free DNA-based multi-cancer early detection	42
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	42
Updating cancer research with patient-focused networks	42
Advancing cancer precision surgery with the tumor coagulome	41
RHOA takes the RHOad less traveled to cancer	41
Molecular and clinical insights into early-onset endometrial cancer	40
Targeting the mitochondrial unfolded protein response in cancer: opportunities and challenges	40
Stress granules and hormetic adaptation of cancer	40
Emerging mechanisms of telomerase reactivation in cancer	40

Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	40
A macrophage-neutrophil program drives mammary carcinogenesis	39
Advisory Board and Contents	39
Advisory Board and Contents	39
Advisory Board and Contents	39
Advisory Board and Contents	39
Subscription & copyright page	39
Cross-dressing of dendritic cells strengthens antitumor immunity	38
Time-of-day dependency of adoptive cell therapies	38
CAR T cell persistence in cancer	38
Beyond safety: suicide systems in cell-based cancer therapies	38
A tipping point in cancer epidemiology: embracing a life course exposomic framework	37
Functional heterogeneity of fibroblasts in primary tumors and metastases	37
Targeting TIM-3 to halt lung precancer progression	37
Dissecting liver tumor heterogeneity to improve health equity	36
Leveraging space innovations for cancer breakthroughs on Earth	36
RNA vaccines for cancer: revolutionizing immunization strategies	36
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	35
Immune response and inflammation in cancer health disparities	35
Advisory Board and Contents	35
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	35
Subscription & copyright page	35
Neoantigen-directed therapeutics in the clinic: where are we?	35
Advisory Board and Contents	34
Clonal evolution and hierarchy in myeloid malignancies	34
Engineered bacterial therapeutics for detecting and treating CRC	33
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	33
Space in cancer biology: its role and implications	32
Epigenetic basis and targeting of cancer metastasis	31
Ferroptosis vulnerability in FLT3-mutant leukemia	31
Dying to survive: harnessing inflammatory cell death for better immunotherapy	30
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	29
Advisory Board and Contents	29
Addressing the genetic/nongenetic duality in cancer with systems biology	28
Subscription & copyright page	28
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	28
Immunomodulation by endothelial cells: prospects for cancer therapy	27
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	27
Subscription & copyright page	27
The development of therapy related myeloid neoplasms in childhood cancer survivors	27
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	27
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	27
NETscape or NEThance: tailoring anti-cancer therapy	27
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	26
Lifileucel: the first cellular therapy approved for solid tumours	26
Next-generation cancer vaccines and emerging immunotherapy combinations	26
Genitourinary cancer neoadjuvant therapies: current and future approaches	26
Deciphering the roles of ABCB5 in normal and cancer cells	25
Successfully targeting the cancer system with metronomics for medulloblastoma	25
Subscription & copyright page	25
Persisting cancer cells are different from bacterial persisters	25
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	25
Embracing diversity: macrophage complexity in cancer	24
Future perspectives on engineered T cells for cancer	24
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome	24
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis	23
Tissue architecture in tumor initiation and progression	23
How cancer cells make and respond to interferon-I	23
The extracellular matrix in cancer: from understanding to targeting	23
Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer	22
Enhancing dendritic cells by inhibiting BCL2	22
Subscription & copyright page	22
Emerging and extensive clonal evolution in the pancreas	22
Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance	21
TET2, tumor control, and CAR T cell hyperproliferation	21
Fueling the revolution: RIBOTACs manipulating RNA decay	21
Think zebras: challenges and opportunities for treating rare cancers	21
Defining obesity in the context of cancer: thinking beyond body mass index	21